Thursday, May 25, 2017 11:50 PM
|
CCSVI in Multiple Sclerosis
Sadly, this news is not a surprise. Monoclonal antibody therapies (like Ocrevus and Tysabri) leave the brain vulnerable to serious infections like the JC virus and PML. Here's more from my blog. http://ccsviinms.blogspot.com/2016/05/ocrelizumab-and-wrapping-up-ms.htmlBut the case could be attributable to 'carryover' from the patient's previous treatment with natalizumab, the company said.
|